Revelation Biosciences Inc. (REVB)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
1. 18
+0.05
+4.4248%
$
4.06M Market Cap
- P/E Ratio
- Div Yield
39,500 Volume
- Eps
$ 1.13
Previous Close Want to track REVB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
REVB closed today higher at $1.18, an increase of 4.4248% from yesterday's close, completing a monthly increase of 7.2727% or $0.08. Over the past 12 months, REVB stock gained 51.2821%.
REVB is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 1.15%. On average, the company has surpassed earnings expectations by 2.2733%, based on the last three reports.
Revelation Biosciences Inc. has completed 5 stock splits, with the recent split occurring on Jan 28, 2026.
The company's stock is traded on one exchange.
REVB Chart
Revelation Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 41 | $49.2 | $44.28 | -$4.92 | -10% |
 Anthony Scaramucci SkyBridge Capital II LLC | 323,241 | $387,889.01 | $352,235.72 | -$35,653.29 | -9.19% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.2 | $1.09 | -$0.11 | -9.17% |
Revelation Biosciences Inc. (REVB) FAQ
What is the stock price today?
The current price is $1.18.
On which exchange is it traded?
Revelation Biosciences Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is REVB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.06M.
Has Revelation Biosciences Inc. ever had a stock split?
Revelation Biosciences Inc. had 5 splits and the recent split was on Jan 28, 2026.
Revelation Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | James Rolke CEO | NASDAQ (CM) Exchange | 76135L804 CUSIP |
| US Country | 8 Employees | - Last Dividend | 28 Jan 2026 Last Split | - IPO Date |
Overview
Revelation Biosciences, Inc. is a pioneering clinical-stage biopharmaceutical company based in San Diego, California, established in 2020. The company's core focus lies in the innovation of immune system therapeutics and diagnostics aimed at a wide array of medical conditions. By harnessing leading-edge science and technology, Revelation Biosciences, Inc. endeavors to develop groundbreaking treatments that address unmet medical needs, focusing on enhancing patients' lives across the globe through improved health outcomes.
Products and Services
Revelation Biosciences, Inc. is at the forefront of developing several therapeutic product candidates, including:
- GEM-SSI: A potential pioneering therapy designed for the prevention and treatment of surgical site infections (SSI). This innovative approach aims to reduce the incidence of post-surgical complications, thereby improving surgical outcomes and patient recovery times.
- GEM-AKI: A potential therapy under development with the aim of preventing and treating acute kidney injury (AKI). By targeting the underlying causes of AKI, this treatment seeks to mitigate the severity and progression of acute kidney damage, offering hope for patients at risk of this condition.
- GEM-CKD: A potential therapy aimed at the prevention and treatment of chronic kidney disease (CKD). Through its innovative mechanism of action, GEM-CKD intends to slow the progression of CKD, thus improving the quality of life for those living with this long-term condition.
Contact Information
Address: 4660 La Jolla Village Drive
Phone: 650 800 3717
Website: https://www.revbiosciences.com
